Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma - Dummer, R; Flaherty, K; Robert, C (J Clin Oncol, 2021)